The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Hologic's revenues will grow 36.6% and EPS will grow 8.8%.
The average estimate for revenue is $645.5 million. On the bottom line, the average EPS estimate is $0.37.
Last quarter, Hologic tallied revenue of $588.5 million. GAAP reported sales were 26% higher than the prior-year quarter's $467.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.37. GAAP EPS were -$0.30 for Q4 versus $0.10 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 64.3%, 230 basis points worse than the prior-year quarter. Operating margin was 12.6%, 620 basis points worse than the prior-year quarter. Net margin was -13.2%, 1,910 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $2.64 billion. The average EPS estimate is $1.58.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 678 members out of 698 rating the stock outperform, and 20 members rating it underperform. Among 195 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 189 give Hologic a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hologic is outperform, with an average price target of $23.68.
Is Hologic the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Hologic to My Watchlist.